Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Back to the List
Type(s) of Cancer
Colorectal
Study Phase
Phase 3
Study Completion Date
2015-04
NCT00303628Uploaded 05-04-2021
Access via NCI by Request
PDS UID: nci-data-467
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation
Provider Information
Provider Data DescriptionThere are five different submissions for PMID 31852811 from trial E5204. This dataset, NCT00303628-D1, contains baseline, treatment, and efficacy data. Dataset NCT00303628-D2 contains toxicity data. Dataset NCT00303628-D3 contains PRO Bowel function/uniscale data. Dataset NCT00303628-D4 contains PRO FACT-Diarrhea Data. Dataset NCT00303628-D5 contains PRO FACT/GOG-Ntx Data.
SponsorECOG-ACRIN Cancer Research Group
Data ProviderNational Cancer Institute
Clinical Trials.gov Information
Brief SummaryDrugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving more than one drug (combination chemotherapy) together with bevacizumab after surgery may kill any tumor cells that remain after surgery. It is not yet known whether oxaliplatin, leucovorin, and fluorouracil is more effective with or without bevacizumab in treating rectal cancer. This randomized phase III trial is studying combination chemotherapy to see how well it works with or without bevacizumab in treating patients who have had surgery for stage II or stage III rectal cancer.
ConditionsAdenocarcinoma of the Rectum
Stage II Rectal Cancer
Stage III Rectal Cancer
Intervention TypeDrug: oxaliplatin
Drug: fluorouracil
Drug: leucovorin calcium
Drug: bevacizumab
Drug(s)Drug: oxaliplatin
Drug: fluorouracil
Drug: leucovorin calcium
Drug: bevacizumab
Total Enrolled355
RandomizationRandomized
Blinding MethodNone
Arms InterventionArm I - Active Comparator
Arm II - Experimental
Secondary IDNCI-2009-00563
PubMed (PMID)N/A
Collaborator(s)National Cancer Institute (NCI)
Region(s)United States
Canada
Peru
Puerto Rico
Age Range18 Years and older (ADULT, OLDER_ADULT)
Files: NCT00303628-D1
Data DictionaryNCT00303628-D1-Data-Dictionary_1.pdf
DATANCT00303628-D1-Dataset_1.csv
OTHERREADME.pdf
Files: NCT00303628-D2
Data DictionaryNCT00303628-D2-Data-Dictionary_1.pdf
DATANCT00303628-D2-Dataset_1.csv
OTHERREADME.pdf
Files: NCT00303628-D3
Data DictionaryNCT00303628-D3-Data-Dictionary_1.pdf
DATANCT00303628-D3-Dataset.csv
OTHERREADME.pdf
Files: NCT00303628-D4
Data DictionaryNCT00303628-D4-Data-Dictionary_1.pdf
DATANCT00303628-D4-Dataset.csv
OTHERREADME.pdf
Files: NCT00303628-D5
Data DictionaryNCT00303628-D5-Data-Dictionary_2.pdf
DATANCT00303628-D5-Dataset.csv
OTHERREADME.pdf
© 2024 Project Data Sphere
All rights reserved
Privacy PolicyTerms of Use